---
title: "Hong Kong Mid-Caps Shift Focus to Shareholder Returns With Buybacks and Dividends"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301693643.md"
description: "Fenbi Group spent nearly HKD 40m in a single-day buyback on June 13, followed by additional repurchases, while Ferretti Group announced a EUR 0.097 per share dividend. Several mid-cap Hong Kong stocks have prioritized capital returns over growth reinvestment in recent weeks."
datetime: "2026-10-13T10:15:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301693643.md)
  - [en](https://longbridge.com/en/news/301693643.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301693643.md)
generator: "portal-rs"
---

# Hong Kong Mid-Caps Shift Focus to Shareholder Returns With Buybacks and Dividends

Hong Kong’s mid-cap stocks are increasingly turning to capital return initiatives amid subdued market conditions. Fenbi Group (2465.HK) executed aggressive share buybacks in June, spending nearly HKD 40 million on June 13 alone—its largest single-day repurchase this year. The company followed up with additional purchases on June 14 and 17, totaling over HKD 50 million in the month. Separately, Ferretti Group (9638.HK) announced a final dividend of EUR 0.097 per share, payable June 26, reflecting steady capital distribution from the luxury yacht maker.

Other notable players like China National Materials (0626.HK) and CHC Healthcare (2142.HK) have maintained capital discipline without recent repurchase programs. CR Beer (0291.HK), Shanghai Fudan Microelectronics (1385.HK), and Zhaojin Mining (1825.HK) have similarly focused on operational execution rather than shareholder returns this quarter. Smaller listings including Tianchen International Medical (2469.HK), Biotech newcomer (89888.HK), and industrial supplier (8280.HK) remain quiet on capital allocation strategies.

The trend highlights a selective approach among mid-tier Hong Kong-listed firms, where capital deployment priorities increasingly align with shareholder value preservation rather than growth reinvestment.

### Related Stocks

- [02465.HK](https://longbridge.com/en/quote/02465.HK.md)
- [09638.HK](https://longbridge.com/en/quote/09638.HK.md)
- [00626.HK](https://longbridge.com/en/quote/00626.HK.md)
- [02142.HK](https://longbridge.com/en/quote/02142.HK.md)
- [02469.HK](https://longbridge.com/en/quote/02469.HK.md)
- [89888.HK](https://longbridge.com/en/quote/89888.HK.md)
- [01385.HK](https://longbridge.com/en/quote/01385.HK.md)
- [00291.HK](https://longbridge.com/en/quote/00291.HK.md)
- [01825.HK](https://longbridge.com/en/quote/01825.HK.md)
- [08280.HK](https://longbridge.com/en/quote/08280.HK.md)

## Related News & Research

- [China Resources Beer Files List of Directors and Board Committee Members](https://longbridge.com/en/news/305960040.md)
- [Harbour BioMed Announces NMPA Acceptance of IND Application for Its First AI-Enabled Drug Candidate LET003 for the Treatment of Overweight or Obesity](https://longbridge.com/en/news/306032412.md)
- [Jiangsu Lopal Tech. Signs New CATL Sales Framework Agreement](https://longbridge.com/en/news/306140236.md)
- [Ferretti invests nearly EUR 30 million to expand Ancona superyacht yard](https://longbridge.com/en/news/305980279.md)
- [Harbour BioMed Appoints Dr. Sanjay Keswani as Scientific Advisor in Neuroscience](https://longbridge.com/en/news/305766056.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**